A Live Attenuated Vaccine Candidate against Emerging Highly Pathogenic Cattle-Origin 2.3.4.4b H5N1 Viruses
Ahmed MostafaiD, Chengjin YeiD, Ramya S. BarreiD, Vinay ShivannaiD, Reagan J. MeredithiD, Roy N. PlattiD, Ruby A. EscobedoiD, Mahmoud M. BayoumiiD, Esmeralda Gracián-CastroiD, Nathaniel D. JacksoniD, Anastasija ČupićiD, Aitor NogalesiD, Tim AndersoniD, Adolfo García‐SastreiD, Luis Martínez‐SobridoiD
Abstract
Influenza viruses present a significant public health risk, causing substantial illness and death in humans each year. Seasonal flu vaccines must be updated regularly, and their effectiveness often decreases due to mismatches with circulating strains. Furthermore, inactivated vaccines do not provide protection against shifted influenza viruses that have the potential to cause a pandemic. The highly pathogenic avian influenza H5N1 clade 2.3.4.4b is prevalent among wild birds worldwide and is causing a multi-state outbreak affecting poultry and dairy cows in the United States (US) since March 2024. In this study, we have generated a NS1 deficient mutant of a low pathogenic version of the cattle-origin human influenza A/Texas/37/2024 H5N1, namely LPhTXdNS1, and validated its safety, immunogenicity, and protection efficacy in a prime vaccination regimen against wild-type (WT) A/Texas/37/2024 H5N1. The attenuation of LPhTXdNS1 in vitro was confirmed by its reduced replication in cultured cells and inability to control IFN{beta} promoter activation. In C57BL/6J mice, LPhTXdNS1 has reduced viral replication and pathogenicity compared to WT A/Texas/37/2024 H5N1. Notably, LPhTXdNS1 vaccinated mice exhibited high immunogenicity that reach its peak at weeks 3 and 4 post-immunization, leading to robust protection against subsequent lethal challenge with WT A/Texas/37/2024 H5N1. Altogether, we demonstrate that a single dose vaccination with LPhTXdNS1 is safe and able to induce protective immune responses against H5N1. Both safety profile and protection immunity suggest that LPhTXdNS1 holds promise as a potential solution to address the urgent need for an effective vaccine in the event of a pandemic for the treatment of infected animals and humans. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=143 HEIGHT=200 SRC="FIGDIR/small/646033v2_ufig1.gif" ALT="Figure 1"> View larger version (27K): org.highwire.dtl.DTLVardef@1ca0d0borg.highwire.dtl.DTLVardef@1e5232org.highwire.dtl.DTLVardef@a6694corg.highwire.dtl.DTLVardef@14b0832_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A One-Shot Multivalent Live-Attenuated Candidate Influenza Vaccine against Divergent Zoonotic H5N1 Clades
Ahmed M. Elsayed, Ramya S. Barre, … Luis Martínez‐Sobrido·bioRxiv·Aug 3, 2026
- Dual-Route H5N1 Vaccination Induces Systemic and Mucosal Immunity in Murine and Bovine Models
Joshua Wiggins, Adthakorn Madapong, Eric A. Weaver·npj VaccinesPeer-reviewed·Apr 21, 2026
- Immunization with a novel RNA replicon vaccine confers long-lasting protection against H5N1 avian influenza virus in 24 bird species
Marianne Stettler, Stefan Hoby, … Gert Zimmer·bioRxiv·Jan 15, 2025
- Mice immunized with N1 neuraminidase in a single cycle infectious virus or in a recombinant nanoparticle vaccine are protected against lethal challenge with highly pathogenic avian influenza H5N1 influenza
Michael S. Piepenbrink, Ramya S. Barre, … James J. Kobie·bioRxiv·Oct 12, 2026
- Detection of low pre-existing humoral immunity against influenza virus H5N1 clade 2.3.4.4b in unexposed individuals
Katharina Daniel, Leon Ullrich, … Florian Klein·ImmunityPeer-reviewed·Jan 30, 2026
- Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus
C. Furey, N. Ye, … S. E. Hensley·bioRxiv·Apr 30, 2023